The Chappel Group Research
Welcome,         Profile    Billing    Logout  
 7 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perez, Jose
NCT03596385 / 2017-002485-40: TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

Active, not recruiting
4
8507
Europe
Beta blocker, atenolol, bisoprolol, carvedilol, metoprolol, nevibolol.
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Myocardial Infarction
01/25
01/25
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
02/25
08/28
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
GLOBAL-AKI, NCT05387811: International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

Completed
N/A
1456
Europe, US, RoW
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Azienda Ospedaliera di Padova
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
09/23
11/23
NCT04780542: Internet-delivered Cognitive Behavioral Treatment of Depression and Anxiety in Latin American College Students

Active, not recruiting
N/A
1500
RoW
Yo Puedo Sentirme Bien- Clinician-Guided version, Yo Puedo Sentirme Bien- Self-Guided version
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente, National Institute of Mental Health (NIMH), Harvard Medical School (HMS and HSDM)
Major Depressive Disorder, Generalized Anxiety Disorder
05/25
06/25
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
N/A
586
Europe, Japan, US, RoW
isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib
Sanofi
Plasma Cell Myeloma
02/26
02/26
Chappel, Christopher M
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ASPIRE, NCT04557046: Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test

Active, not recruiting
N/A
1134
US
Nasal Swab, Nasopharyngeal swab, Throat swab, Fingerstick, Saliva specimen
LumiraDx UK Limited
Covid19
03/21
03/24
NCT05817045: Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Completed
N/A
330
US
RD-X19, Sham
EmitBio Inc.
COVID-19
06/24
06/24
Rodriguez, Mayra
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
Albert, Sara
AIMS, NCT06639477: Assessing Improvements in Mood and Sleep Trial

Not yet recruiting
N/A
420
US
Treatment As Usual, Active Condition, Active Comparator
University of Pittsburgh, Emory University, University of California, Berkeley, University of California, Los Angeles, Augusta University, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Depression, Suicidality, Sleep
08/29
08/30
CARES, NCT05219955: Caregiver Stress and Sleep Study

Recruiting
N/A
120
US
Morning Action Plan Execution, Activity Strategy-based Session with Therapist, Attention-based Session with Therapist, Advance sleep-wake time
University of Pittsburgh, National Institute of Mental Health (NIMH)
Depressive Symptoms, Caregiver Burden
06/26
12/26
Romark
NCT04489381: Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Terminated
3
214
US
Nitazoxanide, NTZ (nitazoxanide), NT-300, Placebo, Vitamin Super B-Complex
Romark Laboratories L.C.
Enterovirus, Rhinovirus
01/21
02/21

Download Options